Module 6: Accountability, Advocacy & Justice
Accountability, Advocacy and Justice describes processes for incorporating monitoring, review, accountability, and transparency, and considers opportunities for action both to uphold commitments and to advance equity by design in clinical research.
Original Release Date: July 15, 2022
Expiration Date: August 15, 2025
Review Date: May 22, 2024 by Willyanne Decormier Plosky, DrPH
Target Audience
This activity is intended for leadership, investigators, practicing providers, clinical trialists, clinical trial staff, nurse practictioners, nurses, research nurse specialists, physician assistants, clinical research coordinators, other frontline staff, regulatory and IRB committee members, and others who design, conduct, report or are responsible for clinical research.
Learning Objectives
Upon completion of this activity, participants will be able to:
- Understand challenge of data analysis with small subgroups
- Identify processes for building review, accountability, and transparency in DEI in clinical research
- Consider a metrics framework for assessment
- Develop strategies to advance and sustain inclusivity in clinical research and equity in health care
Additional Information
PLEASE NOTE: For questions or assistance with any special needs regarding the training course, please contact the MRCT Center at: MRCT@bwh.harvard.edu
YOU MAY ALSO BE INTERESTED IN Interpretation and Application of ICH E6(R2)
Welcome to Version 1.0 of Interpretation and Application of ICH E6(R2) – an online course developed by the MRCT Center with a multi-stakeholder international team of experts.
MANY THANKS TO THE FOLLOWING PEOPLE FOR ACTING AS DISCUSSANTS DURING THIS TRAINING SERIES:
Dr. Ebony Boulware, Professor and Chief, Division of General Internal Medicine, Department of Medicine; Director, Clinical and Translational Science Institute; Vice Dean for Translational Science, Duke Clinical and Translational Science Institute, Duke University
Dr. Lola Fashoyin-Aje, Deputy Division Director, Division of Oncology 3, Office of Oncologic Diseases, OND/CDER; Associate Director, Science and Policy to Address Health Disparities, Oncology Center of Excellence, Food and Drug Administration
This activity is not for credit.